Gilead Signs Global Research Collaboration with Tango to Develop & Commercialize Targeted Immuno-Oncology Therapies
Shots:
- Tango to get $50M upfront plus $1.7B as preclinical fees and milestone payments in addition to royalties in response Gilead has option to license WW rights to five targets developed from Tango’s genomics-based discovery platform
- Additionally- Tango has option to co-develop and co-retain two program from the above five targets in the US & is eligible to receive royalties and milestones payments (ex the US). The profit and cost sharing will be done equally b/w the companies
- The focus of the agreement is to develop next generation targeted immune therapies by combining Tango’s technology + Gilead’s drug discovery platform- for the treatment of cancer
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
